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tntracardiac pacemaker implantation was first described a
alf century ago; the same authors first reported on trans-
elephonic monitoring (TTM) of such devices a dozen years
ater (1,2). Follow-up of the pacemaker patient was recog-
ized as critical, particularly in view of the uncertain
eliability associated with leads and generators. Tracking
evice longevity and function have remained an important
roblem (3,4), compounded by the development of more
idespread indications for pacemakers (5), increasingly
omplex devices, and mounting advisories that attest to an
ver-present threat of premature device failure (6,7). Iron-
cally, the population at risk of device malfunction has
xpanded due to medical and technological advances result-
ng in greater patient and pacemaker longevity. Device
ollow-up technology has also evolved, inevitably raising the
uestion “how are pacemaker patients and their devices best
onitored?”
See page 2012
In-person monitoring has long been the gold standard for
evice follow-up, allowing history taking, physical exami-
ation, electrocardiography, radiography, interrogation, and
eprogramming (8). Automaticity in devices, such as auto-
atic threshold assessment, may alert the physician to the
eed for intensified follow-up and device adjustments and
ay reduce the frequency or duration of office visits. It
annot, however, supplant direct patient/pacemaker evalu-
tion (9).
TTM facilitated the direct patient encounter by allowing
ewer visits and serving as the first form of remote moni-
oring. During nonmagnet electrocardiographic assessment,
TM displays the patient’s free-running rhythm (intrinsic
r paced) and whether appropriate sensing is present.
agnet electrocardiographic assessment evaluates effective
acing capture and provides the magnet rate of the device,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
From the Cardiac Electrophysiology and Pacemaker Laboratory, Hospital of Saint
aphael Yale University School of Medicine, New Haven, Connecticut.seful in tracking generator depletion. Problems with tele-
hone interference must be acknowledged, and only real-
ime information is available: no correlation may be made
etween past events or symptoms and the present transmis-
ion. Very importantly, TTM allows interpersonal interac-
ion, history taking, and communication as to ongoing
atient symptoms or concerns and medication changes.
Early studies with TTM demonstrated its utility in moni-
oring device depletion (10). A subsequent multicenter study
emonstrated that TTM was accurate, with a positive predic-
ive value of 93% for pacemaker failure (11). Guidelines for
onitoring were established by the Centers for Medicare and
edicaid Services, which have not been updated for 25 years
5,12). Others have indicated that device problems could be
dentified throughout the life of a device and may be missed by
TM and that the existing Medicare guidelines may be
nadequate for follow-up (13). What has become increasingly
lear is that TTMmay be useful for detecting battery depletion
14), but is significantly less effective in detecting all compli-
ations when compared with in-office pacemaker follow-up
15). This led to the recommendations by the Canadian
orking Group on Cardiac Pacing that direct patient
ollow-up rather than TTM was desirable (16). Worldwide
urveys in the past have demonstrated a 60% prevalence of
TM use in pacemaker follow-up, although current figures are
acking (17).
Remote monitoring and interrogation for follow-up of
mplantable cardioverter-defibrillators (ICDs), as opposed to
acemaker devices, are relatively new. Depending on the
anufacturer, monitoring is enabled via Internet-based sys-
ems or through radiofrequency transmission from a transmit-
er in the ICD via telephone to a service center. Remarkably,
he feasibility of the technique was only first reported 5 years
go in a prospective study (18), but its application to ICD
ollow-up has become widespread. In contrast to TTM, a host
f information is afforded by this new technology, both
eal-time and historical (19). In particular, all information that
ay be interrogated from devices during the office setting is
etrievable with remote monitoring of ICDs, with the caveat
hat remote manual testing or reprogramming of devices is not
urrently available.
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November 24, 2009:2020–2 Transtelephonic Versus Remote Monitoring of Implantable Electronic DevicesSurprisingly, remote monitoring of pacemakers with this
ame technology has not been as widely used. In this issue
f the Journal, Crossley et al. (20) present the results of the
REFER (Pacemaker Remote Follow-up Evaluation and
eview) study, the first trial designed to evaluate prospec-
ively the efficacy of remote pacemaker interrogation, tradi-
ional TTM, and in-person pacemaker evaluation using
onventional Centers for Medicare and Medicaid Services
uidelines (5,12). They observed an earlier time to first
iagnosis of clinically actionable events (5.7 months vs. 7.7
onths) in remote monitoring compared with TTM. Per-
aps more importantly, only 2% of such events were
dentified by TTM (the remainder found during office
isits) compared with 66% of such events in patients using
he remote monitoring approach.
These findings support the impression that the primary
enefit afforded by TTM is the close evaluation of generator
ongevity, which, given advances in technology and auto-
aticity, assumes importance predominantly as the device
ears its elective replacement indicator. TTM detected few
linically actionable events. Evaluation of pacemaker sens-
ng and/or capture or, alternatively, detection of paroxysmal
rrhythmias may be more problematic using TTM given the
rief “window” afforded by real-time telemetry. In contrast,
emote monitoring allowed the transmission of a host of
etails, both past and present, regarding pacemaker function
nd arrhythmias not retrievable through conventional
TM.
The timely and abundant information afforded by remote
onitoring of pacemakers in particular (and cardiovascular
mplantable electronic devices [CIEDs] in general) is strik-
ng and clearly has an impact on previous guidelines for
evice follow-up (5,12,16). It must be recognized, however,
hat the present study (20) describes the utility of only 1
roprietary system: the applicability of these findings to
ther manufacturers is unclear (and not all devices allow
emote monitoring). In contrast, TTM remains universally
pplicable.
Of separate concern is the definition of clinically action-
ble events (not synonymous with clinically important
vents). Undoubtedly, most practitioners would value the
arlier recognition of elective replacement indicator or
ignificant changes in threshold, impedance, and percentage
f ventricular pacing; ironically, such detections reflect a
inority of the events reported in the present study. In
ontrast, it is less clear what constitutes an arrhythmia
urden significant enough to warrant intervention (how
uch nonsustained ventricular tachycardia and what dura-
ion or rate of atrial fibrillation). Most important, the
uthors have not demonstrated that actions taken in re-
ponse to their remote detections had any effect on overall
orbidity or mortality. No specific information is included
egarding the timing and type of actions taken after clini-
ally actionable event detection.CIED follow-up must address various goals that are patient
elated (optimizing quality of life), CIED related (optimizing
evice function), and disease related (monitoring arrhythmias
nd hemodynamic status). Paradigms for CIED follow-up
ay also reflect patient preference, geographic isolation from
irect follow-up, the patient’s underlying medical condition,
IED reliability, associated advisories, available follow-up
esources, and cost considerations. This has led to a revisiting
f guidelines for CIED monitoring (21). Is TTM an outdated
odality? Is remote monitoring to become the preferred
pproach? Although in-person monitoring has served as the
ainstay of follow-up, it is time to explore how TTM and
emote monitoring may best be used to enhance the lives of
atients with CIEDs and those responsible for their care.
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